Professor, Dept. of Ophthalmology and Visual Sciences
UBC/VGH Eye Care Centre 301
2550 Willow St.
Vancouver, BC V5Z 3N9
work phone: 6048754199

Department of Health Care and Epidemiology


Research Description

Dr. David Maberley is a professor with the University of British Columbia’s Ophthalmology Department. He attended medical school at the University of British Columbia before completing a residency in ophthalmology at the University of Toronto. He subsequently undertook retinal fellowship training at Queen’s University and where he also completed a Masters of Science in Community Health and Epidemiology. Following his training in Kingston, he studied macular diseases and advanced retinal surgical techniques at Columbia University and Manhattan Eye, Ear, and Throat Hospital in New York City.

Dr. Maberley has expertise and performs research in the medical and surgical management of: diabetic retinopathy, macular degeneration, surgical macular disease, complex retinal detachments, and high myopia. He is presently heading the ophthalmology component of the British Columbia First Nations Diabetes Telemedicine project. In April 2000, Dr. Maberley established an eye clinic at the Vancouver Native Health Society (VNHS) to allow increased access to primary and secondary eye care services in the Downtown East Side.

Recent Publications

Ahmadi AA, Chuo J, Banashkevich A, Ma P, Maberley D. The effects of intravitreal vevacizumab on patients with macular edema secondary to branch retinal vein occlusion. Can J Ophthalmol 2009;44:154-159.

Baciu P, Cui, J, Ma P, Maberley D, Matsubara J. Expression of Intergrins on Human Choroidal Neovascular Membranes. Human Press 2009; 2:12-19

Boucher MC, Desroches G, Garcia-Salinas R, Kherani A, Maberley D, Olivier S, Oh M, Stockl F. Teleophthalmology screening for diabetic retinopathy through mobile imaging units within Canada. Can J Ophthalmol 2008;43:658-668.

Chiu JZ, Ma P, Maberley D, Matsubara JA, Samad A. Stage Specificity of Novel Growth Factor Expression During Development of Proliferative Vitreoretinopathy Clinical Study.   Eye 2006;1-9.

Cruess AF, Maberley D, Wong D, Chen J. The treatment of wet AMD in Canada: access to therapy (policy review) Can J Ophthalmol 2009;44:548–56

Cui J, Lei H, Samad A, Basavanthappa S, Maberley D, Matsubara J, Kazlauskas A. PDGF receptors are activated in human epiretinal membranes. Exp Eye Res. 2009;88(3):438-44.

Cui J, Ma P, Maberley D, Matsubara J, Ning A. Expression of Integrins in Human Proliferative Diabetic Retinopathy Membranes. Can J Ophthalmology 2008; Vol. 43 No. 6

Edalati K, Roesch MT, Buchanan ML, Teeter M, Maberley D. Central serous chorioretinopathy and idiopathic nonhistaminergic angioedema. Can J Ophthalmol 2009;44:606-607.

Etminan M, Brophy J, Maberley D. Use of Statins and Angiotensin Converting Enzyme Inhibitors (ACE-Is) and the Risk of Age Related Macular Degeneration: Nested Case-Control Study. Current Drug Safety, 2008 Jan;3(1):24-6. [Not referenced in JCR] {2}

Hollands H, Brox AC, Chang A, Adilman S, Chakraborti B, Kliever G, Maberley DAL . Correctable visual impairment and its impact on quality of life in a marginalized Canadian neighbourhood. Can J Ophthalmol 2009;44:42-48.

Lei H, Velez G, Cui J, Samad A, Maberley D, Matsubara J, Kazlauskas A. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol. 2010 Jul;177(1):132-40. Epub 2010 May 20. [5.673, 0.834]

Maberley D, Albiani D. Burden and health resource utilization in neovascular age-related macular degeneration: A review. Evidence-Based Ophthalmology. 9(1):58-60, January 2008. [Not referenced in JCR] {1}

Maberley D. Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration. A randomized clinical trial. Ophthalmology 2009;116(11):2149-2157.

Ning A, Cui J, Maberley D, Ma P, Matsubara J. Expression of integrins in human proliferative diabetic retinopathy membranes. Can J Ophthalmol 2008;43:683-688.

Wittenberg L, Maberley D, Ma P. Wade NK, Gill H, White V. Contribution of Vitreous Cytology to Final Clinical Diagnosis: Fifteen Year Review of Vitreous Cytology Specimens from One Institution. Ophthalmology 2008. In Epub ahead of print. Available online 31 July, 2008. [4.621, 0.792] {2}

Yeung SN, Blicker JA, Maberley DA. Postoperative inflammation as the presenting sign of latent syphilis. Ocul Immunol Inflamm. 2008 May-Jun;16(3):119-20. [1.054, 0.059] {2}

Yeung SN, Paton KE, Waite C, Maberley DA. Intravitreal bevacizumab for iris neovascularization following proton beam irradiation for choroidal melanoma. Can J Ophthalmol. 2010 Jun;45(3):269-73. [1.028,0.160]

Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, Greve M, Kozousek V, Lam WC, Maberley DA. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of diabetic retinopathy. Can J Ophthalmol. 2012 Apr;47(2 Suppl):S1-30, S31-54.

Hooper P, Boucher MC, Cruess A, Dawson KG, Delpero W, Greve M, Kozousek V, Lam WC, Maberley DA. Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Diabetic Retinopathy – executive summary. Canadian Ophthalmological Society Diabetic Retinopathy Clinical Practice Guideline Expert Committee. Can J Ophthalmol. 2012 Apr;47(2):91-6.

Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012 Apr 4;307(13):1414-9.

Etminan M, Forooghian F, Maberley D. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study. Etminan M, Forooghian F, Maberley D. CMAJ. 2012 May 15;184(8):E431-4. Epub 2012 Apr 2.

Etminan M, Maberley D, Mikelberg FS. Use of topiramate and risk of glaucoma: a case-control study. Am J Ophthalmol. 2012 May;153(5):827-30. Epub 2012 Jan 20.

Lei H, Rheaume MA, Cui J, Mukai S, Maberley D, Samad A, Matsubara J, Kazlauskas A. A novel function of p53: a gatekeeper of retinal detachment. Am J Pathol. 2012 Sep;181(3):866-74.

Wong PC, Fung AT, Gerrie AS, Moloney G, Maberley D, Rossman D, White V, Collins D, Coupland R, Chen LY. IgG4-Related Disease with Hypergammaglobulinemic Hyperviscosity and Retinopathy. Eur J Haematol. 2012 Dec 22. doi: 10.1111/ejh.12059. [Epub ahead of print]

Lei H, Rheaume MA, Cui J, Mukai S, Maberley D, Samad A, Matsubara J, Kazlauskas  A novel function of p53: a gatekeeper of retinal detachment. A. Am J Pathol. 2012 Sep;181(3):866-74.

Miguel AI, Henriques F, Azevedo LF, Loureiro AJ, Maberley DA. Systematic review of Purtscher’s and Purtscher-like retinopathies. Eye (Lond). 2013 Jan;27(1):1-13. doi: 10.1038/eye.2012.222. Epub 2012 Nov 23.

Pennock S, Kim D, Mukai S, Kuhnle M, Chun DW, Matsubara J, Cui J, Ma P, Maberley D, Samad A, Van Geest RJ, Oberstein SL, Schlingemann RO, Kazlauskas A. Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease. Am J Pathol. 2013 May;182(5):1659-70. doi: 10.1016/j.ajpath.2013.01.052. Epub 2013 Apr 9.

Hua W, Cao S, Cui J, Maberley D, Matsubara J. Analysis of reasons for noncompliance with laser treatment in patients of diabetic retinopathy. Can J Ophthalmol. 2013 Apr;48(2):88-92. doi: 10.1016/j.jcjo.2012.09.012.

Forooghian F, Maberley D, Albiani DA, Kirker AW, Merkur AB, Etminan M. Uveitis risk following oral fluoroquinolone therapy: a nested case-control Study. Ocul Immunol Inflamm. 2013 Oct;21(5):390-3. doi: 10.3109/09273948.2013.808351. Epub 2013 Jul 22.